EA200701159A1 - Комбинированное лекарственное средство, включающее телмисартан и гидрохлортиазид - Google Patents

Комбинированное лекарственное средство, включающее телмисартан и гидрохлортиазид

Info

Publication number
EA200701159A1
EA200701159A1 EA200701159A EA200701159A EA200701159A1 EA 200701159 A1 EA200701159 A1 EA 200701159A1 EA 200701159 A EA200701159 A EA 200701159A EA 200701159 A EA200701159 A EA 200701159A EA 200701159 A1 EA200701159 A1 EA 200701159A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydrochlorthiazide
telmisartan
combined medicine
medicine including
hydrochlorothiazide
Prior art date
Application number
EA200701159A
Other languages
English (en)
Inventor
Хелмут Э. Сумахер
Петер Бём
Аксель Ридель
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200701159(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA200701159A1 publication Critical patent/EA200701159A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)

Abstract

В заявке описана фармацевтическая композиция, включающая примерно 80 мг телмисартана и примерно 25 мг гидрохлортиазида или примерно 160 мг телмисартана и примерно 50 мг гидрохлортиазида, предназначенная для лечения гипертензии у пациентов с недостаточным снижением артериального давления при лечении или антагонистом ангиотензинового рецептора II, или фармацевтической композицией, включающей антагонист ангиотензинового рецептора II и низкую дозу гидрохлортиазида.
EA200701159A 2004-12-17 2005-12-09 Комбинированное лекарственное средство, включающее телмисартан и гидрохлортиазид EA200701159A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17
PCT/EP2005/013224 WO2006063737A1 (en) 2004-12-17 2005-12-09 Combination therapy comprising telmisartan and hydrochlorothiazide

Publications (1)

Publication Number Publication Date
EA200701159A1 true EA200701159A1 (ru) 2007-12-28

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701159A EA200701159A1 (ru) 2004-12-17 2005-12-09 Комбинированное лекарственное средство, включающее телмисартан и гидрохлортиазид

Country Status (15)

Country Link
EP (1) EP1827424A1 (ru)
JP (1) JP2008524136A (ru)
KR (1) KR20070097511A (ru)
CN (1) CN101080225A (ru)
AR (1) AR052052A1 (ru)
AU (1) AU2005315855A1 (ru)
BR (1) BRPI0519656A2 (ru)
CA (1) CA2589493A1 (ru)
EA (1) EA200701159A1 (ru)
IL (1) IL183944A0 (ru)
NO (1) NO20072325L (ru)
PE (1) PE20060768A1 (ru)
TW (1) TW200637546A (ru)
UY (1) UY29274A1 (ru)
WO (1) WO2006063737A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
RU2465916C2 (ru) * 2007-10-19 2012-11-10 Оцука Фармасьютикал Ко., Лтд. Твердый фармацевтический препарат матричного типа
WO2009058950A2 (en) 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
EP2252273B1 (en) 2008-03-19 2016-12-28 ratiopharm GmbH Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
NZ590948A (en) * 2008-07-31 2012-06-29 Takeda Pharmaceutical Solid pharmaceutical composition comprising a diuretic, ph control agent and an oxadiazole
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
SI2443094T1 (sl) 2009-06-19 2013-08-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo telmisartana
EP2448576A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) * 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (tr) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
WO2014119767A1 (ja) * 2013-01-31 2014-08-07 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
JP6422868B2 (ja) * 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬
CN106562973A (zh) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 一种抗高血压药物复方制剂
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN108653227A (zh) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 一种替米沙坦氢氯噻嗪片及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
AU2002242676B2 (en) * 2002-01-16 2008-05-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof

Also Published As

Publication number Publication date
CN101080225A (zh) 2007-11-28
PE20060768A1 (es) 2006-09-29
BRPI0519656A2 (pt) 2009-03-03
TW200637546A (en) 2006-11-01
UY29274A1 (es) 2006-07-31
IL183944A0 (en) 2007-10-31
NO20072325L (no) 2007-07-06
JP2008524136A (ja) 2008-07-10
KR20070097511A (ko) 2007-10-04
EP1827424A1 (en) 2007-09-05
AU2005315855A1 (en) 2006-06-22
WO2006063737A1 (en) 2006-06-22
AR052052A1 (es) 2007-02-28
CA2589493A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
EA200701159A1 (ru) Комбинированное лекарственное средство, включающее телмисартан и гидрохлортиазид
AU2003210300A1 (en) The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
EP2248519A3 (en) Non-mucoadhesive film dosage forms
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
EP2322217A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
EA201100544A1 (ru) Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
WO2007146900A3 (en) Antihypertensive therapy method
WO2007098387A3 (en) Antihypertensive therapy
CY1118486T1 (el) Λαπατινιμπη για τη θεραπεια του καρκινου
AR038858A1 (es) Combinacion
NO20071889L (no) Middel for profylakse eller behandling av stoffskiftesyndrom.
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
BRPI0717306A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento, prevenção ou alívio de uma doença ou um distúrbio ou uma condição de um corpo de animal vivo.
TH83710B (th) การบำบัดรวม
TH83710A (th) การบำบัดรวม
WO2009062128A3 (en) Combination drug therapy for the treatment of cancer
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung